Chemistry:Ampreloxetine
From HandWiki
Ampreloxetine (INN, USAN; developmental code name TD-9855) is a selective norepinephrine reuptake inhibitor (NRI) which is under development for the treatment of symptomatic neurogenic orthostatic hypotension (NOH).[1][2][3]
It shows high affinity for both the norepinephrine transporter (NET) and the serotonin transporter (SERT), with 4-fold selectivity for the NET over the SERT, and is thought to act as a dual serotonin–norepinephrine reuptake inhibitor (SNRI) at higher doses.[3][4]
As of November 2023, ampreloxetine is in phase 3 clinical trials for NOH.[1] The drug was also under development for the treatment of attention deficit hyperactivity disorder (ADHD) and fibromyalgia, but development for these uses was discontinued.[1][5]
References
- ↑ 1.0 1.1 1.2 "Ampreloxetine - Theravance Biopharma". 21 November 2023. https://adisinsight.springer.com/drugs/800026474.
- ↑ "Ampreloxetine Versus Droxidopa in Neurogenic Orthostatic Hypotension: A Comparative Review". Cureus 15 (5). May 2023. doi:10.7759/cureus.38907. PMID 37303338.
- ↑ 3.0 3.1 "Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor". Int J Neuropsychopharmacol 18 (2). December 2014. doi:10.1093/ijnp/pyu027. PMID 25522383.
- ↑ Cite error: Invalid
<ref>tag; no text was provided for refs namedKanodiaLoBaldwin2021 - ↑ "Emerging drugs for the treatment of attention-deficit hyperactivity disorder (ADHD)". Expert Opin Emerg Drugs 25 (4): 395–407. December 2020. doi:10.1080/14728214.2020.1820481. PMID 32938246.
 |  |
